KRAS and neoplasm: That SLC22A18 functions as a tumor suppressor is strongly supported by down-regulated expression in CRC, but it remains to be determined if the protein can inhibit cell cycle progression or KRAS signaling in other types of cancer cells, particularly in those where mutations of SLC22A18 have been found.